Clinical trialNCT04477291TerminatedPhase 1Interventional

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

SponsorAptose Biosciences Inc.Enrollment45Acute Myeloid LeukemiaMyelodysplastic Syndromes

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Rafael Bejar, MD, PhD
Aptose Biosciences Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope National Medical Center
Duarte, California, United States
University of Southern California
Los Angeles, California, United States
University of Miami
Miami, Florida, United States
Northwestern University
Chicago, Illinois, United States
Ochsner Healthcare
New Orleans, Louisiana, United States
Atlantic Hematological Oncology Center
Morristown, New Jersey, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University Hospital of Cleveland
Cleveland, Ohio, United States
University of Texas Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CG-806

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Oct 2020
Primary completion: 15 Apr 2024
Completion: 15 Apr 2024
Last update posted: 7 Mar 2025
Registered enrollment: 45
Registry id: NCT04477291

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.